All In Biotech

Drug Trial Radar · NCT06736704

SNV4818 in Participants With Advanced Solid Tumors

A Phase 1/2, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination With Other Anticancer Agents in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Mar 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

320

Planned (sponsor's estimate)

Start

Feb 20, 2025

Primary completion

Apr 2027

Study completion Jun 2027

Sponsor

Lead sponsor
Pikavation Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Dec 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is testing a new medicine, SNV4818, for people with advanced cancers. The researchers want to find out if SNV4818 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the safest and most effective one.

Conditions

  • Advanced Solid Tumors

Interventions

  • SNV4818Drug

    SNV4818 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.

  • FulvestrantDrug

    Fulvestrant is administered via an intramuscular injection. It will be given at a dose of 500 mg (2-250 mg/5 mL injections)

  • PalbociclibDrug

    Palbociclib tablets will be administered by mouth on days 1-21 of a 28 day cycle. The Palbociclib starting dose will be 125 mg once-daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose limiting toxicities (DLTs)Time frame: First 28 days of study treatment
  2. Treatment Emergent Adverse Events (TEAEs)Time frame: From first SNV4818 dose through approximately 30 days following the last SNV4818 dose

Locations

12 sites in 3 countries. Site status is shown where the registry gives one.

  • The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate

    Los Angeles, California · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Thomas Jefferson University-Sidney Kimmel Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Recruiting

  • The University of Texas M.D. Anderson Cancer Center

    Houston, Texas · Recruiting

  • Chris O'Brien Lifehouse

    Camperdown, New South Wales, Australia · Recruiting

  • Scientia Clinical Research

    Randwick, New South Wales, Australia · Recruiting

  • Monash Health

    Clayton, Victoria, Australia · Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia · Recruiting

  • Linear Clinical Research

    Nedlands, Western Australia, Australia · Recruiting

  • The Ottawa Hospital Cancer Centre

    Ottawa, Ontario, Canada · Recruiting

  • University Health Network, Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.